Industry
Biotechnology
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Loading...
Open
13.05
Mkt cap
2.2B
Volume
1.1M
High
13.58
P/E Ratio
-7.36
52-wk high
21.00
Low
13.00
Div yield
N/A
52-wk low
8.33
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 10:06 am
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 10:26 am
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 1:57 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 11:26 am
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 9:40 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.